TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 14, 2016, details the results of the annual meeting of stockholders held by TG Therapeutics, Inc. The meeting took place at the offices of Alston & Bird LLP in New York, New York.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders representing 39,853,756 shares (73.63% of the 54,124,279 shares entitled to vote) were present in person or by proxy. All three proposals submitted to the vote were approved:
- Proposal 1 (Election of Directors): Seven individuals were elected to the Board of Directors to serve until the 2017 annual meeting. The directors elected are Michael S. Weiss, Laurence N. Charney, William J. Kennedy, Mark Schoenebaum, MD, Yann Echelard, Kenneth Hoberman, and Daniel Hume.
- Proposal 2 (Ratification of Auditors): CohnReznick LLP was approved as the independent registered public accountant for the fiscal year ending December 31, 2016.
- Proposal 3 (Executive Compensation): The advisory vote on the compensation of named executive officers was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific voting percentages for each director nominee, as "Votes Withheld" varied among candidates.
- Confirm the tenure of the newly elected directors, which extends until the 2017 annual meeting.
- Note the significant number of Broker Non-Votes (9,938,705) recorded for the director elections and the executive compensation proposal.
- Review the definitive proxy statement dated April 29, 2016, for detailed descriptions of the proposals and director biographies.